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REPORT OF RISING POWERS POLICY WORKSHOP: 
MODELS OF BIOMEDICAL INNOVATION AND CONSUMER DEMAND 
 
Held on 29 May 2014 at King’s College London 
 
This report has been compiled by Saheli Datta  
and approved by the workshop participants 
  
A policy workshop was held on 29 May 2014 at King’s College London as part of the ESRC 
funded research ‘State strategies of governance in biomedical innovation: the impact of 
China and India’. This project explores emerging innovation dynamics and trans-national 
governance in the context of the increasing importance of the life sciences and technologies 
in countries’ and regions’ competitive and collaborative economic strategies, and the 
recognition that biomedical sciences raise difficult questions of ethics and of social impact. 
The project involves a series of workshops, whose results are designed to inform public 
policy-making in a range of fields in regenerative and personalized medicine in the UK and 
the ‘Rising Powers’ of India and China. This workshop was the fourth in the series (Beijing, 
2013 and New Delhi, 2014) and the second to be held in London since 15 March 2013.  
  
The workshop was chaired by the research Principal Investigator Brian Salter, Professor of 
Politics in the Department of Political Economy, King’s College London and supported by 
Research Associate Dr Yinhua Zhou and PhD Researcher and Coordinator Ms Saheli Datta.   
Attendance was by invitation only. The invitees, sixteen in total, ranging from clinicians, 
academics, researchers, lawyers, bioethicists and regulators, represented a wide range of 
public and private sector organizations including National Institute of Health and Care 
Excellence (NICE), Cell Therapy Catapult (CTC), Intercytex, Kinetics Corporation 
Incorporated, Association of British Healthcare Industries, DeBRA International (patient 
organization), Lawford Davies and Denoon, University Hospital of South Manchester, 
University of Exeter, University of Manchester, Cardiff Business School, King’s College 
London and Spanish Research Council.  
 
The objective of the workshop was to better understand the extent to which 
new models of innovation responsive to consumer demand may be constructed within the 
existing regulatory framework? Traditionally, the model of innovation employed in 
biomedicine has been driven by the preferences and concerns of the supply-side – principally 
science, medicine and industry. However, the advent of a global market in healthcare where 
consumers make their own choices regarding the treatment they want, when, where and 
how, has energized a demand side view of what the innovation process should look like. 
Cell therapy is not immune from these developments and new models of innovation have 
emerged, particularly in the emerging economies, which deliver new treatments on a much 
shorter timescale than that offered by the traditional model. As a result, there is now a 
vibrant global market in cell therapies fuelled by a supply side employing non-traditional 
models of innovation.  
   
The exclusion of North America, Europe and Japan from much of this new market because 
of their adherence to the traditional innovation model raises important political, regulatory 
and ethical issues that this workshop aimed to address with the objective of moving the 
debate forward in a constructive and practical manner, focusing in particular on the UK’s 
position.  The workshop opened with an analysis of “Health consumers, markets and cell 
therapy innovation: the global context” by Professor Brian Salter (presentation attached). 
The presentation looked at the political forces shaping innovation models in the global 
market of cell therapies, focusing on the role of consumers in this market and how it shapes 
the demand-supply relationship and the nature of the market’s engagement with different 
models of stem cell therapy innovation (see Salter, Zhou and Datta, 2014a; 2014b).  
 
The second session subjected this analysis to ethical scrutiny, drawing out the value 
assumptions that underlie competing innovation models and identifying the ethical 
implications of a shift towards a more consumer oriented approach. Professor Christine 
Hauskeller, Senior Lecturer at the University of Exeter, Exeter, UK, provided the bioethical 
perspective- the patient as a consumer and “the ethics of innovation: balancing protection 
and participation” (presentation attached).  
 
Given this political and ethical context with its associated challenges and opportunities, the 
final session addressed the position of the UK in the cell therapy market and the ability of its 
regulatory structures to respond to the economic and political demands of the global 
competition for advantage. Dr Paul Kemp, Chief Executive and Chief Scientific Officer at 
Intercytex and involved in commercial regenerative medicine for over 25 years, provided the 
industry perspective “combining scientific and medical innovation into the progressive 
translation of cellular therapies” (presentation attached).  
 
This report is organised as follows. We begin with an outline of the issues identified and 
questions raised by each presentation. This is followed by a brief report of the discussion 
from the perspective of the patient-as-a-consumer-of-health-services, the regulator, the 
bioethicist and the industry. Finally we conclude that introducing flexibilities in the current 
innovation model towards more patient-industry interaction and a more democratic patient-
clinician relationship presents the best way forward to stem steadily declining translation 
rates from stem cell research to therapies. The workshop helps provide pointers for future 
research and policy development to understand the ‘global biopolitics’ of consumer-demand 
and policy implications of this innovative field.  
 
ISSUES IDENTIFIED BY THE WORKSHOP 
1) Political forces shaping innovation models in the global market of cell therapies.   
Professor Salter’s introductory presentation “Health consumers, markets and cell therapy 
innovation: the global context” (presentation attached) sought to discuss key issues as below,  
 What should be the role of the health consumer in cell therapy 
innovation? 
 To what extent is the consumer demand for new therapies reflected 
in political demands for new or revised models of innovation? 
 What is the contribution of practice based models of medical 
innovation to a more consumer friendly approach to innovation. 
 What are the implications of consumer demand for the roles of 
scientists, clinicians and industrialists in cell therapy innovation? 
 What regulatory changes would enhance the capacity of consumers to 
make informed choices and risk judgements about cell therapies? 
 
2) Ethical implications of a shift towards a more consumer oriented approach. 
Professor Christine Hauskeller, Senior Lecturer at the University of Exeter, Exeter, UK, a 
bioethicist, provided the perspective of the patient as a consumer- “the ethics of innovation: 
balancing protection and participation” (presentation attached). The presentation sought to 
discuss the issues below,  
 The patient as consumer 
 The needs and expectations of patients and the legitimacy of 
authoritative institutions – science, medicine, regulators 
 Who decides the best way forward for cell therapy? 
 Non-linear innovation. Successful medical therapies are dependent 
on their consumers, the patients, in different way than other 
innovations. 
 The consumers ability to judge their own best interest 
 Ethical issue relating to unequal access to resources 
 Should individuals be free/encouraged to travel in order to get what 
they (and possibly their doctor) believe could benefit them? 
 
3) UK’s competitiveness in the current regulatory environment.  
Dr Paul Kemp, Chief Executive and Chief Scientific Officer at Intercytex and involved in 
commercial regenerative medicine for over 25 years, provided the industry perspective 
“combining scientific and medical innovation into the progressive translation of cellular 
therapies” (presentation attached). The presentation sought to discuss the issues below,  
Issues 
 How can existing legislation, UK, EU and ROW best be utilised to 
accelerate iterative development of effective therapies? 
 The role of the practice of medicine in cell therapy. How can this be 
used to develop the best treatment protocol and how can this inform 
pivotal clinical studies?  
 The role of the patient in the development process 
 Progressive reimbursement. What sources are available? How would 
pricing be determined? How could risk sharing be used? 
 How can the clinician/industrial interface be used in order to inform 
product development and application within the current legislative 
framework? 
 Managing ethics, hype, conflicts of interest and social perceptions 
 Threats and opportunities of medical tourism to the UK landscape 




The perspective of the patient as a consumer 
The patient perspective centered on the need to increase the responsiveness of the existing 
model of bioinnovation in general and stem cell therapy in particular to patient needs and 
demands. Patient organizations, representing the patient’s voice, felt that ‘much’ more 
needed to be done in terms of current healthcare innovation systems’ responsiveness to 
patient needs. The patients’ feeling about the existing innovation models responsiveness, as 
expressed by the patient organisations and a few clinicians, is a pervading ‘paternalistic’ 
attitude that necessarily assumes patients as passive agents or ‘listeners’ with little agency 
either in understanding or making personal healthcare decisions who need to be told, by 
clinicians and regulators, what is best for them. Furthermore, patients view current 
regulatory environments as ‘rationing access’ of patients to innovative treatments and attach 
less importance to ‘quality’ and ‘regulatory controls,’ in comparison to regulators and 
bioethicists. The inherent emasculation of patients, as without agency, by the medical and 
scientific community is a view increasingly shared by a number of empirical studies of 
patient networks, patient-run blogs, chat rooms, social media etc (Chen and Gottweis, 2013; 
Elkin, 2008; Fox and Duggan, 2013; Morgan et.al, 2011). Furthermore, patient’s feel that 
current research programmes in UK unfairly privilege ‘intervention based research’ rather 
than ‘preventive treatments-based research’ and that this direction needs to change not only 
to save on costly interventions including hospitalization and care costs but also for a 
healthier Britain.  
 
The regulatory perspective 
From the regulatory perspective, there was an acknowledgement of the need, from patients 
and the industry, for ‘more’ systemic flexibilities in the existing innovation model both in 
terms of democratizing patient access as well as increasing UK’s competitiveness in the 
global bioeconomy. The recent introduction (in April 2014) of systemic flexibilities like the 
fast-tracking of the innovative pathway through Promising Innovative Medicine (PIM) and 
Early Access to Medicines Scheme (EAMS) along with existing regulatory arrangements like 
‘specials,’ and ‘hospital exemptions,’ were cited as examples of regulatory efforts to address 
issues of patient access while making UK companies more competitive. The regulatory 
move, from stringently regulated case-by-case assessment approach of the existing ‘specials’ 
and ‘hospital exemption’ to a more generic and less case-by-case-based assessment approach 
of the recently launched PIM and EMAS, were cited as a reiteration of the regulatory 
apparatus’ willingness to increase responsiveness to increasingly elastic consumer demand 
for innovative treatments. In turn, the responsiveness of the previously inflexible regulatory 
apparatus, served to affirm not only the regulators acknowledgement of the pervading 
‘paternalism’ of the existing model with regards to patient access but also the need for 
change.  
On their part, regulators felt that ‘risk averse’ Research and Steering Committees1, averse to 
being seen as the ‘one’ that approved a research that ‘went wrong,’ posed a significant 
challenge for change initiatives. In summary, the push for further systemic flexibilities 
appeared to be well underway, from the regulators view, with the UK Medicines and 
Healthcare Regulator Agency (MHRA) expressing keen interest in working with the EU to 
introduce changes that would further narrow the ‘valley of death’ while improving public 
access to innovative treatments like ‘experimental’ stem cell therapies.   
 
The bioethical perspective 
 The bioethical view, hinged on the patient narrative, was presented in two divergent strands. 
One view was that the ethics of stem cell science as practiced in India and China, referring to 
patients being given unproven stem cell treatments and stem cell clinics “trading on hope” 
(Qiu, 2009) ran ‘parallel’ to that in the west. This view is well established in literature (Taylor 
                                                 
1 Expert groups responsible for assessing suitability of innovative therapies (e.g. ethical, legal, social 
aspects, scientific merit etc) before progressing it to the next phase of the innovation process. 
et.al, 2008; Murdoch and Scott, 2010; Pownall, 2010). This view necessarily assumes patients 
to be passive agents unable to make the ‘right’ personal healthcare choices and rejects 
notions of the patient as ‘consumers’ that is as socio-economic agents with political agency 
in an increasingly demand driven global ‘bioeconomy.’ The other view, questions the 
traditional power relations between the ‘passive patient’ subordinated to the ‘knowledge 
expert clinician,’ and considers the patient as a well-informed and an important socio-
political and economic actor with agency to make rational personal healthcare decisions. The 
latter view is grounded in the fact that patients no longer suffer from information 
asymmetries commonly associated with the snake-oil healers and quacks of the 17th and 18th 
centuries. Rather, recent studies show that patients achieve unprecedented levels of 
knowledge gain from the internet, social media, chat rooms, blogs, online healthcare 
resources etc (Adams, 2011; Gottweis & Chen, 2014).  
 
The industry perspective 
The view from industry focused on current regulations restricting commercial entities’ access 
to patients and held as partly responsible for low translation rates from clinical trials to 
marketing licences. Two instances of regulatory restrictions were held as major roadblocks. 
First, the fact that industry (private sector developers of new drugs and therapies) is 
prevented from talking to patients involved in clinical trials prevents them from receiving 
key feedback about the intervention under trial and the trialling process. The view is that 
access to key patient feedback and related clinical trial data through a closely regulated 
interactive process can turnaround declining translation rates from research to therapeutic 
products. Second, the fact that industry is unable to ‘talk’ to clinicians to pursue 
commercialization efforts of a successful ‘experiment’ or ‘trial’2 presents a roadblock to 
better translation rates. The view is that flexibilities in this area, provided it is stringently 
regulated and monitored to prevent abuse, could see greater commercialization successes. 
Furthermore, these flexibilities could make UK based small and medium enterprises, 
currently responsible for most of the downstream commercialization activities of stem cell 
research in the UK, more competitive globally. However, a profound and concomitant 
appreciation of the ‘ethical pot’ involved in deregulating clinician-industry linkages was 
voiced along with the need for stringent checks and balances to make deregulation ‘work’ for 
the benefit of the Regenerative Medicine (RM) industry. In this regard, it was felt that 
separating the different components of RM, like cell therapy, transplantation medicine, non-
cell therapy based interventions like cancer care, medical devices, wound care etc, in popular 
discourse, policy documents, media would help to ‘free’ areas of RM that had little to do 
with human embryonic stem cells but are currently lumped together in the same ‘ethical 
meting pot’ surrounding ‘embryo research.’  
 
The way forward 
Introducing flexibilities in the current innovation model towards more patient-industry 
interaction and a more democratic patient-clinician relationship were considered the best 
way forward. Moving towards medical governance with ‘self governance is on its way out,’ 
e.g. using enforceable regulations of medical practitioners and clinicians, was suggested as a 
possible model of democratising the patient-clinician relationship while protecting both 
                                                 
2 Under current regulations, commercial entities restricted from approaching clinicians to pursue 
commercialization efforts after a successful product trial. However, the reverse is allowed, that is 
clinicians are allowed to approach commercial entities for commercialization following trials. 
patients and clinicians from malpractice and abuse. In this regard, the recently launched 
Japanese model allowing drugs or therapies proven ‘safe’ to be tested over a seven year 
period for ‘efficacy’ by clinicians in real world (i.e. non-clinical trial) settings, provided a 
possible alternative to the existing model. However, the fact that changes in Japanese 
regulations were industry driven rather than being driven by patient groups was considered 
thought provoking. It was felt that a model of innovation closely resembling the Japanese 
model, but using a licensing scheme for clinicians to allow for a ‘gradual emergence of 
efficacy,’ could be used in the UK to increase commercialization prospects of its extensive 
stem cell research capabilities.  
 
In terms of pointers for future research, exploring the various aspects of transnational 
governance and policy development to understand the ‘global biopolitics’ of consumer-
demand and policy implications of this innovative field is important. Notably, research into 
the intricacies of transnational governance in stem cell research, using the case study of stem 
cell research and therapies in China and India, is being conducted by Ms Saheli Datta for her 
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